Breaking News, Collaborations & Alliances

AlzProtect & PAREXEL Biotech Enter Collaboration

For the performance of the clinical phase 2a development of AZP2006 for the treatment of PSP, a rare degenerative disease of the brain

ALZPROTECT announced that PAREXEL Biotech, a new division of PAREXEL International Corporation, has been selected to perform the clinical phase 2a development of AZP2006 for the treatment of PSP, a rare degenerative disease of the brain. PAREXEL Biotech will fulfill AlzProtect’s needs related to the completion of their Phase 2a clinical study from protocol writing to the coordination of patient recruitment.   “It was important for us to work with an internationally renowned partner cover...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters